- Home
- OTLK vs ZDAI Comparison
OTLK vs ZDAI Comparison
Compare OTLK & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | ZDAI |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | Hong Kong |
| Employees | N/A | 33 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | General Bldg Contractors - Nonresidential Bldgs |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 35.4M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | ZDAI |
|---|---|---|
| Price | $0.44 | $4.15 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.83 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 468.1K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,726.70 | N/A |
| Revenue Next Year | $80.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.20 |
| 52 Week High | $3.39 | $6.56 |
Technical Indicators
Market Signals| Indicator | OTLK | ZDAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 66.63 |
| Support Level | $0.39 | $0.39 |
| Resistance Level | $0.46 | $4.71 |
| Average True Range (ATR) | 0.03 | 0.49 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 68.45 | 17.50 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.